Abstract
Small for GA (SGA) children are at risk for developing the metabolic syndrome. Those who do not catch up, and remain short (SSGA), may benefit from GH therapy. 11β Hydroxysteroid dehydrogenase type 1 (11β-HSD-1) is expressed in visceral fat and is implicated in metabolic morbidity. We hypothesized that SSGA children will have increased basal and glucocorticoid (GC)-stimulated 11β-HSD-1 activity. Twenty SSGA children, aged 7.1 ± 1 y (mean ± SD), were studied before and while on GH therapy and compared with 12 normal age-matched controls. 11β-HSD-1 activity was evaluated by gas chromatography mass spectrometry (GCMS) of urinary steroid product/substrate ratios. GC-stimulated 11β-HSD-1 activity was assessed after overnight dexamethazone (DEX), by oral cortisone conversion to cortisol. In SSGA children, 11β-HSD-1 activity was lower (p < 0.05) and GC-stimulated activity enhanced. SSGA children had maximal cortisol generation of 883 ± 108 compared with 690 ± 63 nmol/L in controls (p < 0.04). GH treatment suppressed 11β-HSD-1 activity. GC-stimulated enzyme activity correlated negatively with GA (r = −0.53, p < 0.01) and birth weight (r = −0.55, p < 0.01). SSGA is associated with enhanced GC-stimulated 11β-HSD-1 activity. This may be programmed in utero, as it is not a function of body composition or secondary metabolic derangement. GH therapy normalizes GC-stimulated 11β-HSD-1 activity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- a-C/b-C:
-
α cortol/β cortol
- a-CL/b-CL:
-
α cortolone/β cortolone
- allo THF:
-
5 α tetrahydrocortisol
- DEX:
-
dexamethazone
- GC:
-
glucocorticoids
- GCMS:
-
gas chromatography mass spectrometry
- hGH:
-
human GH
- 11β-HSD-1:
-
11-beta hydroxysteroid dehydrogenase type 1
- SDS:
-
Standard Deviation Score
- SGA:
-
small for GA
- SSGA:
-
short small for GA
- THE:
-
tetrahydrocortisone
- THF:
-
tetrahydrocortisol
References
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL 1995 Children born small for gestational age: do they catch up?. Pediatr Res 38: 267–271
Karlberg J, Albertsson-Wikland K 1995 Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 38: 733–739
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A 2007 Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 92: 804–810
Dahlgren J, Wikland KA 2005 Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 57: 216–222
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2003 Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 88: 3584–3590
Barker DJ, Bull AR, Osmond C, Simmonds SJ 1990 Fetal and placental size and risk of hypertension in adult life. BMJ 301: 259–262
Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ 1989 Weight in infancy and death from ischaemic heart disease. Lancet 2: 577–580
Eriksson JG, Forsen T, Tuomilehto J, Winter PD, Osmond C, Barker DJ 1999 Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ 318: 427–431
Mericq V, Ong KK, Bazaes R, Pena V, Avila A, Salazar T, Soto N, Iniguez G, Dunger DB 2005 Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia 48: 2609–2614
Saenger P, Czernichow P, Hughes I, Reiter EO 2007 Small for gestational age: short stature and beyond. Endocr Rev 28: 219–251
Fagerberg B, Bondjers L, Nilsson P 2004 Low birth weight in combination with catch-up growth predicts the occurrence of the metabolic syndrome in men at late middle age: the Atherosclerosis and Insulin Resistance study. J Intern Med 256: 254–259
Jaquet D, Deghmoun S, Chevenne D, Collin D, Czernichow P, Levy-Marchal C 2005 Dynamic change in adiposity from fetal to postnatal life is involved in the metabolic syndrome associated with reduced fetal growth. Diabetologia 48: 849–855
Veening MA, Van Weissenbruch MM, Delemarre-Van De Waal HA 2002 Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab 87: 4657–4661
Tenhola S, Martikainen A, Rahiala E, Herrgard E, Halonen P, Voutilainen R 2000 Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. Pediatr Res 48: 623–628
Hokken-Koelega AC, De Waal WJ, Sas TC, Van Pareren Y, Arends NJ 2004 Small for gestational age (SGA): endocrine and metabolic consequences and effects of growth hormone treatment. J Pediatr Endocrinol Metab 17: 463–469
Arends NJ, Boonstra VH, Duivenvoorden HJ, Hofman PL, Cutfield WS, Hokken-Koelega AC 2005 Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA). Clin Endocrinol (Oxf) 62: 44–50
Cianfarani S, Ladaki C, Geremia C 2006 Hormonal regulation of postnatal growth in children born small for gestational age. Horm Res 65: 70–74
Clark PM, Hindmarsh PC, Shiell AW, Law CM, Honour JW, Barker DJ 1996 Size at birth and adrenocortical function in childhood. Clin Endocrinol (Oxf) 45: 721–726
Murphy VE, Smith R, Giles WB, Clifton VL 2006 Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr Rev 27: 141–169
Tenhola S, Martikainen A, Rahiala E, Parviainen M, Halonen P, Voutilainen R 2002 Increased adrenocortical and adrenomedullary hormonal activity in 12-year-old children born small for gestational age. J Pediatr 141: 477–482
Phillips DI, Walker BR, Reynolds RM, Flanagan DE, Wood PJ, Osmond C, Barker DJ, Whorwood CB 2000 Low birth weight predicts elevated plasma cortisol concentrations in adults from 3 populations. Hypertension 35: 1301–1306
Cianfarani S, Geremia C, Scott CD, Germani D 2002 Growth, IGF system, and cortisol in children with intrauterine growth retardation: is catch-up growth affected by reprogramming of the hypothalamic-pituitary-adrenal axis?. Pediatr Res 51: 94–99
Economides DL, Nicolaides KH, Linton EA, Perry LA, Chard T 1988 Plasma cortisol and adrenocorticotropin in appropriate and small for gestational age fetuses. Fetal Ther 3: 158–164
Tenhola S, Turpeinen U, Halonen P, Hamalainen E, Voutilainen R 2005 Association of serum lipid concentrations, insulin resistance index and catch-up growth with serum cortisol/cortisone ratio by liquid chromatography tandem mass spectrometry in children born small for gestational age. Pediatr Res 58: 467–471
Cianfarani S, Germani D, Rossi L, Argiro G, Boemi S, Lemon M, Holly JM, Branca F 1998 IGF-I and IGF-binding protein-1 are related to cortisol in human cord blood. Eur J Endocrinol 138: 524–529
Fruchter O, Zoumakis E, Alesci S, De Martino M, Chrousos G, Hochberg Z 2006 Intracrine modulation of gene expression by intracellular generation of active glucocorticoids. Steroids 71: 1001–1006
Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z 2003 Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88: 385–393
Agha A, Monson JP 2007 Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin Endocrinol (Oxf) 66: 459–465
Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP 1998 The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) 48: 153–162
Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM 1999 Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84: 4172–4177
Paulsen SK, Pedersen SB, Jorgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, Richelsen B 2006 Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 91: 1093–1098
Tiosano D, Knopf C, Koren I, Levanon N, Hartmann MF, Hochberg Z, Wudy SA 2008 Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity. Eur J Endocrinol 158: 385–392
Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84: 1022–1027
Stewart PM, Corrie JE, Shackleton CH, Edwards CR 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82: 340–349
Palermo M, Shackleton CH, Mantero F, Stewart PM 1996 Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 45: 605–611
Neel JV 1962 Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”?. Am J Hum Genet 14: 353–362
Hales CN, Barker DJ 1992 Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35: 595–601
Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM 1993 Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36: 62–67
Jansson T, Powell TL 2007 Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond) 113: 1–13
Dodic M, Moritz K, Wintour EM 2003 Prenatal exposure to glucocorticoids and adult disease. Arch Physiol Biochem 111: 61–69
Simmons RA 2007 Developmental origins of diabetes: the role of epigenetic mechanisms. Curr Opin Endocrinol Diabetes Obes 14: 13–16
Sai S, Esteves CL, Kelly V, Michailidou Z, Anderson K, Coll AP, Nakagawa Y, Ohzeki T, Seckl JR, Chapman KE 2008 Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. Mol Endocrinol 22: 2049–2060
Jamieson PM, Chapman KE, Seckl JR 1999 Tissue- and temporal-specific regulation of 11beta-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo. J Steroid Biochem Mol Biol 68: 245–250
Ward AM, Syddall HE, Wood PJ, Chrousos GP, Phillips DI 2004 Fetal programming of the hypothalamic-pituitary-adrenal (HPA) axis: low birth weight and central HPA regulation. J Clin Endocrinol Metab 89: 1227–1233
Dahlgren J, Boguszewski M, Rosberg S, Albertsson-Wikland K 1998 Adrenal steroid hormones in short children born small for gestational age. Clin Endocrinol (Oxf) 49: 353–361
Putignano P, Pecori Giraldi F, Cavagnini F 2004 Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J Endocrinol Invest 27: 969–974
Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ 2004 Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101: 7088–7093
Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus C, Baier LJ, Permana PA 2004 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47: 1088–1095
Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect “Cushing's disease of the omentum”?. Lancet 349: 1210–1213
Andrew R, Phillips DI, Walker BR 1998 Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83: 1806–1809
Tiosano D, Eisentein I, Militianu D, Chrousos GP, Hochberg Z 2003 11 beta-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J Clin Endocrinol Metab 88: 379–384
Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S 2004 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89: 4755–4761
Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM 1999 Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33: 1364–1368
Meas T, Carreira E, Wang Y, Rauh M, Poitou C, Clement K, Dotsch J, Levy-Marchal C 2010 11beta-hydroxysteroid dehydrogenase type 1 of the subcutaneous adipose tissue is dysregulated but not associated with metabolic disorders in adults born small for gestational age. J Clin Endocrinol Metab 95: 3949–3954
Dalla Pozza RD, Bechtold S, Putzker S, Bonfig W, Netz H, Schwarz HP 2006 Young adults born small for gestational age: is reduced baroreceptor sensitivity a risk factor for hypertension?. Clin Cardiol 29: 215–218
Buske-Kirschbaum A, Krieger S, Wilkes C, Rauh W, Weiss S, Hellhammer DH 2007 Hypothalamic-pituitary-adrenal axis function and the cellular immune response in former preterm children. J Clin Endocrinol Metab 92: 3429–3435
Acknowledgements
The authors are indebted to Novonordisk Israel for compassionate provision of Norditropin Simplexx.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zuckerman-Levin, N., Tsivlin, L., Knopf, C. et al. 11β–Hydroxysteroid Dehydrogenase Type 1 Activity in Short Small-For-GA Children and in Response to GH Therapy. Pediatr Res 70, 208–212 (2011). https://doi.org/10.1203/PDR.0b013e3182226a0c
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/PDR.0b013e3182226a0c
